ARCT
BEARISH
$6.68
Live
Arcturus Therapeutics Holdings Inc. · NASDAQ
Target $23.44
(+251.0%)
$5.85
52W Range
$24.17
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$189.87M
P/E
N/A
ROE
-28.9%
Profit margin
-80.2%
Debt/Equity
0.12
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.
Key Strengths
Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Debt/Equity ratio of 0.12 is low, indicating minimal leverage risk
Recent quarterly earnings surprises have been positive in several quarters, including a +74.6% surprise in Q4 2024
Key Risks
Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)
ROE of -28.92% and ROA of -15.50% reflect inefficient use of capital and deteriorating profitability
No free cash flow or operating cash flow data available, suggesting inability to generate sustainable cash from operations
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
30
20
15
10
0
AI Verdict
bearish
Key drivers: Piotroski F-Score of 0/9, Negative revenue and earnings growth, Negative profitability across all metrics, Lack of cash flow generation, High volatility and long-term price decline
Confidence
85%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.89 suggests trading below book value
- Low market cap ($0.19B) may attract speculative interest
Watchpoints
- No Graham Number or intrinsic value available due to negative earnings and lack of stable growth
- Price/Sales of 2.31 is elevated for a company with negative revenue growth
- Forward P/E of -1.61 indicates no earnings-based valuation support
Future
20/100
Ref Growth rates
Positives
- Analyst target price of $23.44 implies strong growth expectations
- Recent quarters show positive earnings surprises, suggesting potential for recovery
Watchpoints
- Revenue growth is -68.4% YoY, indicating ongoing business contraction
- Earnings growth is not available, but historical trends show erratic and negative performance
- No clear path to profitability or sustainable revenue generation
Past
15/100
Ref Historical trends
Positives
- Some quarters show significant positive earnings surprises (e.g., +253.1% in 2023-Q1)
- Historical EPS growth was positive in 2021-2022, though volatile
Watchpoints
- Most recent Q/Q EPS growth is -110.2%, indicating worsening performance
- 5-year price change of -87.2% reflects prolonged underperformance
- Persistent losses and declining margins over multiple years
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/equity ratio (0.12) and high current/quick ratios (6.64, 6.50) indicate strong liquidity
- No Altman Z-Score available, but low leverage reduces immediate bankruptcy risk
Watchpoints
- Piotroski F-Score of 0/9 is the lowest possible, indicating complete failure in financial health criteria
- Negative ROE, ROA, and ROIC suggest capital is being destroyed
- No operating or free cash flow data implies inability to fund operations sustainably
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio available
- Dividend strength is 0/100, indicating no dividend policy
- Negative earnings make dividend payments impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$6.68
Analyst Target
$23.44
Upside/Downside
+251.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ARCT and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Primary
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
|
SMTI
Sanara MedTech Inc.
Peer
|
-25.6% | -56.6% | -29.4% | -26.5% | +11.3% | +25.6% |
|
RNAC
Cartesian Therapeutics, Inc.
Peer
|
-93.8% | -80.8% | -33.0% | -21.9% | +5.9% | +17.7% |
|
ACB
Aurora Cannabis Inc.
Peer
|
-96.9% | -52.9% | -20.2% | -29.6% | -0.3% | -2.3% |
|
ADAG
Adagene Inc.
Peer
|
-81.2% | +188.8% | +109.6% | +84.4% | +33.2% | +45.4% |
ARC
Arcturus Therapeutics Holdings Inc.
Primary
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
SMT
Sanara MedTech Inc.
Peer
5Y
-25.6%
3Y
-56.6%
1Y
-29.4%
6M
-26.5%
1M
+11.3%
1W
+25.6%
RNA
Cartesian Therapeutics, Inc.
Peer
5Y
-93.8%
3Y
-80.8%
1Y
-33.0%
6M
-21.9%
1M
+5.9%
1W
+17.7%
ACB
Aurora Cannabis Inc.
Peer
5Y
-96.9%
3Y
-52.9%
1Y
-20.2%
6M
-29.6%
1M
-0.3%
1W
-2.3%
ADA
Adagene Inc.
Peer
5Y
-81.2%
3Y
+188.8%
1Y
+109.6%
6M
+84.4%
1M
+33.2%
1W
+45.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.61
PEG Ratio
N/A
P/B Ratio
0.89
P/S Ratio
2.31
EV/Revenue
-0.2
EV/EBITDA
0.22
Market Cap
$189.87M
Profitability
Profit margins and return metrics
Profit Margin
-80.19%
Operating Margin
-435.06%
Gross Margin
-36.79%
ROE
-28.92%
ROA
-15.5%
Growth
Revenue and earnings growth rates
Revenue Growth
-68.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.12
Low debt
Current Ratio
6.64
Strong
Quick Ratio
6.5
Excellent
Cash/Share
$8.12
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-03-03
$-1.03
-36.4% surprise
2025-11-10
$-0.49
+38.7% surprise
2025-08-11
$-0.34
+59.8% surprise
Healthcare Sector Comparison
Comparing ARCT against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-28.92%
This Stock
vs
-88.14%
Sector Avg
-67.2%
(Below Avg)
Profit Margin
-80.19%
This Stock
vs
-16.28%
Sector Avg
+392.6%
(Superior)
Debt to Equity
0.12
This Stock
vs
2.66
Sector Avg
-95.6%
(Less Debt)
Revenue Growth
-68.4%
This Stock
vs
124.04%
Sector Avg
-155.1%
(Slower)
Current Ratio
6.64
This Stock
vs
4.47
Sector Avg
+48.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | |
|
SMTI
Sanara MedTech Inc.
|
BEARISH | $190.4M | - | -1.8% | -36.4% | $20.77 | Compare |
|
RNAC
Cartesian Therapeutics, Inc.
|
BEARISH | $186.62M | - | -% | -% | $7.04 | Compare |
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $194.51M | - | -15.5% | -22.5% | $3.43 | Compare |
|
ADAG
Adagene Inc.
|
BULLISH | $194.65M | - | -63.3% | -% | $4.13 | Compare |
ARCT
Arcturus...
BEARISH
Mkt Cap
$190M
P/E
-
ROE
-28.9%
Price
$6.68
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
9 analysts
Citigroup
2026-03-05
Buy
Buy
Citigroup
2026-03-04
Neutral
Neutral
Piper Sandler
2026-03-04
Overweight
Overweight
Citigroup
2026-01-06
Neutral
Neutral
Citigroup
2025-11-13
Neutral
Neutral
Piper Sandler
2025-11-11
Overweight
Overweight
HC Wainwright & Co.
2025-11-11
Neutral
Neutral
HC Wainwright & Co.
2025-10-24
Buy
Neutral
Citigroup
2025-10-23
Buy
Neutral
Wells Fargo
2025-10-23
Overweight
Overweight
Past News Coverage
Recent headlines mentioning ARCT from our newsroom.
Newest → oldest
No matching news yet.